For Quick Alerts
ALLOW NOTIFICATIONS  
For Daily Alerts

Alembic Pharmaceutic - Rhizen Pharmaceuticals announces Exclusive Worldwide License Agreement for the Development and Commerc

By Religare
|

Alembic Pharmaceuticals Ltd has informed BSE regarding a Press Release dated December 09, 2015 titled "Rhizen Pharmaceuticals announces Exclusive Worldwide License Agreement for the Development and Commercialization of a Dual PI3K-delta gamma Inhibitor".

Story first published: Thursday, December 10, 2015, 12:10 [IST]
Company Search
Get Instant News Updates
Enable
x
Notification Settings X
Time Settings
Done
Clear Notification X
Do you want to clear all the notifications from your inbox?
Settings X
We use cookies to ensure that we give you the best experience on our website. This includes cookies from third party social media websites and ad networks. Such third party cookies may track your use on Goodreturns sites for better rendering. Our partners use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on Goodreturns website. However, you can change your cookie settings at any time. Learn more